{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:40:44Z","timestamp":1788316844655,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clinthera.2024.04.013","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T07:23:25Z","timestamp":1716535405000},"page":"851-854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Newer Glucose-Lowering Drugs and Risk of Gout: A Network Meta-Analysis of Randomized Outcomes Trials"],"prefix":"10.1016","volume":"46","author":[{"given":"Aihua","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.clinthera.2024.04.013_bib0001","doi-asserted-by":"crossref","first-page":"e1358","DOI":"10.1097\/MD.0000000000001358","article-title":"Individuals with type 2 diabetes mellitus are at an increased risk of gout but this is not due to diabetes: a population-based cohort study","volume":"94","author":"Wijnands","year":"2015","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.clinthera.2024.04.013_bib0002","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.clinthera.2024.04.013_bib0003","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1111\/bcp.15344","article-title":"The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: a systematic review and meta-analysis","volume":"88","author":"Najafi","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"10296","key":"10.1016\/j.clinthera.2024.04.013_bib0004","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.clinthera.2024.04.013_bib0005","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00592-022-01866-3","article-title":"Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis","volume":"59","author":"Banerjee","year":"2022","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.clinthera.2024.04.013_bib0006","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2024.04.013_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109080","article-title":"Association between novel glucose-lowering drugs and risk of Asthma: a network Meta-Analysis of cardiorenal outcome trials","volume":"183","author":"Wang","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2024.04.013_bib0008","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.clinthera.2024.04.013_bib0009","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"},{"key":"10.1016\/j.clinthera.2024.04.013_bib0010","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2017047","article-title":"Network meta-analysis: application and practice using Stata","volume":"39","author":"Shim","year":"2017","journal-title":"Epidemiol Health"},{"issue":"10","key":"10.1016\/j.clinthera.2024.04.013_bib0011","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.clinthera.2024.04.013_bib0012","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"issue":"2","key":"10.1016\/j.clinthera.2024.04.013_bib0013","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Res Synth Methods"},{"issue":"8","key":"10.1016\/j.clinthera.2024.04.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.30885","article-title":"Gout flares and mortality after sodium-glucose cotransporter-2 inhibitor treatment for gout and type 2 diabetes","volume":"6","author":"Wei","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.clinthera.2024.04.013_bib0015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/M19-2610","article-title":"Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.clinthera.2024.04.013_bib0016","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2024.04.013_bib0017","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar1907","article-title":"Epidemiology, risk factors, and lifestyle modifications for gout","volume":"8","author":"Saag","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2024.04.013_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112515","article-title":"Empagliflozin reduces oxidative stress through inhibition of the novel inflammation\/NHE\/[Na(+)]c\/ROS-pathway in human endothelial cells","volume":"146","author":"Uthman","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clinthera.2024.04.013_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100502","article-title":"Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection","volume":"14","author":"Michos","year":"2023","journal-title":"Am J Prev Cardiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182400105X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182400105X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T20:02:33Z","timestamp":1732392153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182400105X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S014929182400105X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.04.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Newer Glucose-Lowering Drugs and Risk of Gout: A Network Meta-Analysis of Randomized Outcomes Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}